Immune cell therapy takes on tough scleroderma
NCT ID NCT07493395
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early trial tests whether a single infusion of anti-CD19 CAR T-cells can improve skin thickening and other symptoms in 6 adults with severe, treatment-resistant systemic sclerosis. Participants receive chemotherapy before the infusion and are monitored for 24 months. The study focuses on safety and how the cells behave in the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Anti-CD19 CAR T-cells (a type of immune cell therapy)
What this could lead to
If it works, this could point toward a new treatment option for people with severe scleroderma that hasn't responded to other drugs.
What could go wrong
This is a very early, small trial with only 6 participants, so results may not apply to everyone. CAR T-cell therapy can cause serious side effects like cytokine release syndrome.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCLERODERMA, SYSTEMIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
APHP Necker
NOT_YET_RECRUITINGParis, France
Contact
Contact Email: •••••@•••••
-
CHRU Lille
NOT_YET_RECRUITINGLille, France
Contact Email: •••••@•••••
Contact
-
Chu Rouen
NOT_YET_RECRUITINGRouen, France
Contact Email: •••••@•••••
-
Montpellier University Hospital
RECRUITINGMontpellier, France
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••